Compare Citius Pharmaceuticals Inc (CTXR) vs Vanguard S&P 500 Growth Index Fund ETF (VOOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Vanguard S&P 500 Growth Index Fund ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Vanguard S&P 500 Growth Index Fund ETF trades at $83.18. The key difference: Vanguard S&P 500 Growth Index Fund ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | VOOG | |
|---|---|---|
Market Cap | $14.64M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $1.82 | $85.11 |
52-Week Low | $0.53 | $65.32 |
Enterprise Value | $10.86M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
VOOG (Vanguard S&P 500 Growth ETF) trades at $82.02, down 1.55% on the day, with a bullish technical signal from moving averages. The ETF recently completed a 1:6 stock split on April 21, 2026, making shares more accessible. Technical indicators show neutral oscillators but bullish moving average alignment, with support clustered around $82.
The ETF's outlook remains positive given its focus on S&P 500 growth stocks and low 0.07% expense ratio. Key risks include technology sector concentration and market volatility. Recent financial media coverage highlights VOOG's strong long-term performance potential compared to peer growth ETFs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Vanguard S&P 500 Growth Index Fund ETF
VOOG is an index-based ETF that tracks the S&P 500 Growth Index, composed of the growth-oriented companies within the S&P 500. It selects constituents based on three key metrics—sales growth, the ratio of earnings change to price, and momentum—offering a highly liquid and low-cost way to capture the high-performing 'growth slice' of the broader U.S. large-cap market.
Read more on VOOG →
